Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
Sign Up to like & getrecommendations! Published in 2022 at "Gut and Liver"
DOI: 10.5009/gnl220050
Abstract: Background/Aims Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regarding nocturnal acid breakthrough… read more here.
Keywords: nocturnal acid; regarding nocturnal; acid; dexlansoprazole regarding ... See more keywords